Listen to an interview with Dr. Deborah Wong as she shares her expert insights on the current evidence and latest guidelines for immune checkpoint inhibitor (ICIs) use in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). She also discusses how patient- and disease-specific factors can inform individualized treatment decisions.
The expert:
Dr. Deborah Wong, University of California, Los Angeles (UCLA), CA, USA
This activity is funded by an independent medical education grant from Coherus Oncology, Inc.
This activity is jointly provided by USF Health and touchIME.
Podden och tillhörande omslagsbild på den här sidan tillhör
touchpodcast. Innehållet i podden är skapat av touchpodcast och inte av,
eller tillsammans med, Poddtoppen.
